Fig. 3: miR-221/222 loss is strongly associated with worse survival outcome following treatment. | Blood Cancer Journal

Fig. 3: miR-221/222 loss is strongly associated with worse survival outcome following treatment.

From: Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

Fig. 3

A Pearson correlation of miR-221 and miR-222 levels in the screening cohort. B–D Kaplan–Meier survival curves for overall survival (OS) of the screening cohort (B), as well as of Kruykov et al. (C) and Aass et al. (D) validation cohorts. p values calculated by log-rank test. Forest plots of the univariate (E) and multivariate (F) Cox regression analysis for the OS of the patients. Multivariate analysis adjusted for miR-221/222 levels, R-ISS stage, high-risk cytogenetics, LDH, B2M, and creatinine levels, HDM/ASCT, gender, and age. Internal validation was performed by bootstrap Cox proportional regression analysis based on 1000 bootstrap samples. HR: Hazard Ratio, 95% CI: 95% confidence interval of the estimated HR.

Back to article page